140 related articles for article (PubMed ID: 25236989)
1. Impact of mental health comorbidities on health care utilization and expenditure in a large US managed care adult population with ADHD.
Kawatkar AA; Knight TK; Moss RA; Sikirica V; Chu LH; Hodgkins P; Haim Erder M; Nichol MB
Value Health; 2014 Sep; 17(6):661-8. PubMed ID: 25236989
[TBL] [Abstract][Full Text] [Related]
2. Health care resource utilization and costs associated with psychiatric comorbidities in adult patients with attention-deficit/hyperactivity disorder.
Schein J; Cloutier M; Gauthier-Loiselle M; Bungay R; Chen K; Chan D; Childress A
J Manag Care Spec Pharm; 2024 Jun; 30(6):588-598. PubMed ID: 38824634
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
4. Impact of a Step Therapy for Guanfacine Extended-Release on Medication Utilization and Health Care Expenditures Among Individuals Receiving Treatment for ADHD.
Suehs BT; Sikirica V; Mudumby P; Dufour R; Patel NC
J Manag Care Spec Pharm; 2015 Sep; 21(9):793-802, 802a-802i. PubMed ID: 26308226
[TBL] [Abstract][Full Text] [Related]
5. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder.
Secnik K; Swensen A; Lage MJ
Pharmacoeconomics; 2005; 23(1):93-102. PubMed ID: 15693731
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebec.
Lachaine J; De G; Sikirica V; Van Stralen J; Hodgkins P; Yang H; Heroux J; Ben Amor L
Can J Psychiatry; 2014 Nov; 59(11):597-608. PubMed ID: 25565476
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and incidence of adult attention deficit/hyperactivity disorder in a large managed care population.
Knight TK; Kawatkar A; Hodgkins P; Moss R; Chu LH; Sikirica V; Erder MH; Nichol MB
Curr Med Res Opin; 2014 Jul; 30(7):1291-9. PubMed ID: 24597796
[TBL] [Abstract][Full Text] [Related]
8. Economic Burden of Attention-Deficit/Hyperactivity Disorder among Pediatric Patients in the United States.
Gupte-Singh K; Singh RR; Lawson KA
Value Health; 2017 Apr; 20(4):602-609. PubMed ID: 28408002
[TBL] [Abstract][Full Text] [Related]
9. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
Asche CV; Joish VN; Camacho F; Drake CL
Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
[TBL] [Abstract][Full Text] [Related]
11. Medical Expenditures Associated with Attention-Deficit/Hyperactivity Disorder Among Adults in the United States by Age, 2015-2019.
Witrick B; Zhang D; Su D; Li Y; McCall WV; Hendricks B; Shi L
J Gen Intern Med; 2023 Jul; 38(9):2082-2090. PubMed ID: 36781580
[TBL] [Abstract][Full Text] [Related]
12. Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis.
Libutzki B; Ludwig S; May M; Jacobsen RH; Reif A; Hartman CA
Eur Psychiatry; 2019 May; 58():38-44. PubMed ID: 30802682
[TBL] [Abstract][Full Text] [Related]
13. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population.
Bollinger ME; Diette GB; Chang CL; Stephenson JJ; Sajjan SG; Fan T; Allen-Ramey FC
Clin Ther; 2010 Jun; 32(6):1093-102. PubMed ID: 20637964
[TBL] [Abstract][Full Text] [Related]
14. Attention-deficit/hyperactivity disorder in children: excess costs before and after initial diagnosis and treatment cost differences by ethnicity.
Ray GT; Levine P; Croen LA; Bokhari FA; Hu TW; Habel LA
Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1063-9. PubMed ID: 17018466
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003.
Sankaranarayanan J; Puumala SE; Kratochvil CJ
Curr Med Res Opin; 2006 Aug; 22(8):1475-91. PubMed ID: 16870073
[TBL] [Abstract][Full Text] [Related]
17. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.
Yermakov S; Davis M; Calnan M; Fay M; Cox-Buckley B; Sarda S; Duh MS; Iyer R
J Med Econ; 2015; 18(9):711-20. PubMed ID: 25903661
[TBL] [Abstract][Full Text] [Related]
18. The Israel Survey of Mental Health among Adolescents: prevalence of attention-deficit/hyperactivity disorder, comorbidity, methylphenidate use, and help-seeking patterns.
Farbstein I; Mansbach-Kleinfeld I; Auerbach JG; Ponizovsky AM; Apter A
Isr Med Assoc J; 2014 Sep; 16(9):568-73. PubMed ID: 25351015
[TBL] [Abstract][Full Text] [Related]
19. Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey.
Chan E; Zhan C; Homer CJ
Arch Pediatr Adolesc Med; 2002 May; 156(5):504-11. PubMed ID: 11980558
[TBL] [Abstract][Full Text] [Related]
20. Trends in health care expenditures, utilization, and health status among US adults with spine problems, 1997-2006.
Martin BI; Turner JA; Mirza SK; Lee MJ; Comstock BA; Deyo RA
Spine (Phila Pa 1976); 2009 Sep; 34(19):2077-84. PubMed ID: 19675510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
